Form 10-12B - Registration of securities [Section 12(b)]:
SEC Accession No. 0001047469-13-007989
Filing Date
2013-08-01
Accepted
2013-08-01 16:25:08
Documents
10

Document Format Files

Seq Description Document Type Size
1 10-12B a2216160z10-12b.htm 10-12B 48844
2 EX-10.11 a2216160zex-10_11.htm EX-10.11 1093971
3 EX-10.12 a2216160zex-10_12.htm EX-10.12 183424
4 EX-10.13 a2216160zex-10_13.htm EX-10.13 855441
5 EX-10.14 a2216160zex-10_14.htm EX-10.14 97383
6 EX-99.1 a2216160zex-99_1.htm EX-99.1 1243293
7 G817752.JPG g817752.jpg GRAPHIC 6750
8 G814105.JPG g814105.jpg GRAPHIC 114007
9 G175232KQ01I001.JPG g175232kq01i001.jpg GRAPHIC 3838
10 G175232KOI001.JPG g175232koi001.jpg GRAPHIC 3838
  Complete submission text file 0001047469-13-007989.txt   3700829
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-12B | Act: 34 | File No.: 001-36033 | Film No.: 131003032